TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TScan Therapeutics Inc (TCRX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown significant revenue growth and positive earnings surprises, the stock's technical indicators and lack of strong trading signals suggest limited immediate upside. Additionally, the stock's recent trend indicates a higher probability of short-term declines, making it less suitable for an impatient investor unwilling to wait for optimal entry points.
The MACD histogram is positive at 0.0133, indicating bullish momentum, but it is contracting, suggesting weakening strength. The RSI at 63.438 is neutral, and moving averages are converging, indicating no clear trend. Key support is at 1.009, and resistance is at 1.158. The stock has a 60% chance of declining in the short term based on candlestick pattern analysis.
Hedge funds are significantly increasing their positions, with a 12447.81% rise in buying activity over the last quarter.
The company reported strong Q4 revenue growth of 283.6% YoY, beating expectations.
Analysts have raised the price target to $5, reflecting optimism about upcoming trial results and revenue growth.
Insiders are neutral with no significant trading trends.
The stock has a high probability of short-term declines (-2.41% in the next day, -4.12% in the next week, -10.05% in the next month).
The company is still operating at a net loss (-$35.71 million in Q3 2025), which may deter risk-averse investors.
In Q4 2025, TScan reported revenue of $2.57 million, a 283.6% YoY increase, and a GAAP EPS of -$0.18, beating expectations by $0.06. In Q3 2025, revenue increased by 139.37% YoY, net income improved by 19.48% YoY, and EPS increased by 12.00% YoY. The company shows strong revenue growth but remains unprofitable.
Wedbush maintains an Outperform rating and raised the price target from $4 to $5, citing optimism about upcoming trial results and revenue growth. Analysts view the company positively but acknowledge the speculative nature of its growth prospects.
